VolitionRx (NYSE-A:VNRX) Limited has entered into its first contract for its Nu.Q Vet Cancer Screening Test under a supply and licensing agreement with Singapore-based SAGE Healthcare, a leading distributor of premium veterinary products and services in Asia.
"With the global veterinary market being so fragmented, we determined the best way to ensure our test is accessible worldwide is to have multiple agreements with both large multinationals and regional players," said Dr. Tom Butera, CEO of Volition Veterinary Diagnostics Development, in a statement.
"I am delighted to announce this agreement for centralized labs in Asia, a large and rapidly expanding pet care market. I expect this will be the first of many agreements, including with the big multi-nationals, so that we can cover the whole world through centralized labs and also with point of care."
READ: VolitionRx well positioned with $22.9M as it shifts gears to become a commercial company with products
Dr. Jasmine Kway, CEO of Singapore Volition, said that due to rapid urbanization and rising disposable incomes, pets have become an important part of Asian families.
“Over half of the Asian population have a companion animal with almost a third of households owning a dog,” Dr. Kway said. “We believe that the opportunity for the Nu.Q Vet Cancer Screening Test is huge. SAGE Healthcare is one of the strongest and most respected distributors of leading veterinary brands in Singapore.”
Irene Kum, general manager for SAGE Healthcare Private Limited, added: "Adding the Nu.Q Vet Cancer Screening Test to the routine wellness check-up for older dogs and at-risk breeds could help detect cancer early, when treatment is more effective and affordable. We believe that this is a clear unmet need in the veterinary space. We are excited to launch the test in Singapore in the first quarter of 2022 and with planned subsequent launches in other Asian markets thereafter."
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham